<DOC>
	<DOCNO>NCT00631813</DOCNO>
	<brief_summary>The purpose study determine dose prucalopride safe effective patient chronic constipation . Hypothesis : Prucalopride 1 2 mg bid safe effective treatment chronic constipation whereas 0,5 mg suboptimal dose .</brief_summary>
	<brief_title>Efficacy Safety Study Prucalopride Treatment Chronic Constipation</brief_title>
	<detailed_description>This phase II trial parallel-group design , consist drug-free run-in phase ( phase 1 ) , follow placebo control double-blind phase ( phase 2 ) . Patients receive either R093877 0.5 mg b.i.d. , 1 mg b.i.d . 2 mg b.i.d . placebo period 12 week . Phase 1 run-in period 4 week duration , bowel habit document existence constipation confirm . At start period exist laxative medication withdrawn patient instructed change dietary habit , particular fiber intake trial . Patients enter double-blind phase constipation show present run-in period . If definition constipation meet 4 week run-in period , patient consider ineligible double-blind period . Phase 2 double-blind , randomize , placebo-controlled phase , patient treat 12 week either 0.5 mg , 1 mg 2 mg R093877 placebo give twice daily ( one capsule take breakfast one take even meal ) . Patients admit double blind treatment period randomly allocate one 4 treatment arm .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>1 . Age 1870 year ; 2 . History constipation , i.e. , subject report occurrence two follow criterion least 6 month selection visit : two few spontaneous* bowel movement week , lumpy ( scyballae ) and/or hard stool least ¼ stool , sensation incomplete evacuation least ¼ stool , strain defaecation least ¼ time . *The criterion applicable spontaneous bowel movement i.e. , precede within 24hour period intake laxative agent . Subjects never spontaneous bowel movement consider constipate eligible enter doubleblind phase trial . 3 . Constipation severe cause disability ; subject 's occupational , social recreational activity govern his/her constipation effort attain relief ; 4 . Normal inhibition pattern external anal sphincter strain i.e. , relaxation m.puborectalis distal displacement rectal canal ( digital examination and/or electromyographic and/or manometric evidence acceptable ) ; 5 . Poor result routine laxative treatment diet counselling ; 6 . Constipation functional , i.e. , idiopathic nature ; 7 . Written oral witness informed consent ; 8 . Availability followup trial period . 1 . Constipation think druginduced ; 2 . Presence secondary cause constipation , i.e. , subject suffer type cause constipation idiopathic constipation , instance : endocrine disorder , metabolic disorder , neurologic disorder ; 3 . Congenital megacolon/megarectum ; 4 . History previous abdominal surgery ( hysterectomy , surgery Meckel 's diverticle , appendectomy , cholecystectomy , inguinal hernia repair , splenectomy , nephrectomy fundoplication ) think primary cause constipation ; 5 . Known suspected organic disorder large bowel , i.e. , obstruction , carcinoma inflammatory bowel disease ; 6 . Active proctological condition think responsible constipation ; 7 . Presence follow ECG abnormality : 2nd 3rd degree AVblock , prolong QTtimes ( &gt; 460 m ) , bradycardia ; 8 . Use concomitant medication might cause QTprolongation ; 9 . Use diuretic associated potassium spar effect ; 10 . Known illness condition severe cardiovascular lung disease , neurologic psychiatric disorder ( include substance abuse dependence exception nicotine ) , alcoholism , cancer AIDS gastrointestinal endocrine disorder ; 11 . Impaired renal function ; 12 . Presence serum amylase , serum glutamicoxaloacetic transaminase ( SGOT ) serum glutamicpyruvic transaminase ( SGPT ) concentration &gt; 2 time normal limit ; 13 . Presence clinically significant abnormality blood chemistry , mention 910 , haematology urinalysis selection ; 14 . Pregnancy wish become pregnant trial . ; 15 . Breastfeeding ; 16 . Investigational drug receive 30 day precede trial ; 17 . Inability unwillingness return require followup visit ; 18 . Reliability physical state prevent proper evaluation drug trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>